Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04223843 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Start date: January 8, 2020
Phase: Phase 4
Study type: Interventional

To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow Rate (PIFR). Disease severity (moderate to severe) is based on the Global Initiative for Chronic Lung Disease (GOLD) guidelines (GOLD 2 - 3)

NCT ID: NCT04223830 Completed - Clinical trials for Endoscopic Retrograde Cholangiopancreatography

Initial Case Series With Exalt Single-Use Duodenoscope - Expanded User Experience

Start date: January 14, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to confirm procedural performance of the Exalt Model D Single-Use Duodenoscope in Endoscopic Retrograde Cholangio-Pancreatography (ERCP) and other duodenoscope-based procedures.

NCT ID: NCT04223804 Completed - HIV Infection Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Start date: January 30, 2020
Phase: Phase 1
Study type: Interventional

This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in Human immunodeficiency virus (HIV)-1 infected participants undergoing Antiretroviral therapy (ART) interruption.

NCT ID: NCT04222907 Completed - Clinical trials for Streptococcal Infection Group B as Cause of Diseases Classified Elsewhere (Diagnosis)

The Relationship Between GBS Screening in Pregnant Women Insured in Maccabi Healthcare Services (MHS) and Early-onset Neonatal Disease in Israel

Start date: January 1, 2015
Phase:
Study type: Observational [Patient Registry]

Determination of GBS colonization rates in Pregnant Women insured with Maccabi Health Services, Doctors' Compliance Rates for Referral for Testing, test execution rates, and Early-onset GBS Disease (EOGBSD) Rates in Israel. Determine the relationship between conducting a GBS test in pregnant women and EOGBSD in Israel.

NCT ID: NCT04222738 Completed - Clinical trials for Cardiovascular Benefits of Zingiber Officinale Roscoe in Patients With Type 2 Diabetes Mellitus Before and After 6 Weeks of add-on Therapy

The Cardiovascular Effects of Ginger (Zingiber Officinale) in Patients With Type II Diabetes Mellitus

GINOFF1
Start date: December 1, 2016
Phase: Phase 4
Study type: Interventional

The aim of the study was the evaluation of cardiovascular benefits of Zingiber officinale Roscoe in patients with type 2 diabetes mellitus before and after 6 weeks of add-on therapy.

NCT ID: NCT04222725 Completed - Clinical trials for Post Surgical Ocular Inflammation

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

Start date: February 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.

NCT ID: NCT04222387 Completed - Clinical trials for MEK Inhibitor-Associated Serous Retinopathy

Investigation of Potential Retinal Toxicity Associated With Hair Dye Products Containing pPD Type Aromatic Amines

CAPITOX
Start date: December 19, 2019
Phase: N/A
Study type: Interventional

Hair dye products could induce minimal forms of MEKAR retinopathies (Mitogen-activated Extracellular signal-regulated Kinase - inhibitors associated retinopathies). These minimal forms of MEKAR are likely to be underdiagnosed, since the associated visual loss is usually mild and so this condition should be considered when patients report blurred vision. The aim of the study is to analyze whether in the current population that dyes the hair, minimal forms that go unnoticed by MEKAR retinopathies can be induced.

NCT ID: NCT04221984 Completed - Clinical trials for Intracranial Atherosclerotic Disease (ICAD)

Wingspan One Year Vascular Imaging Events and Neurologic Outcomes

WOVEN
Start date: November 12, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of the study is to determine the one-year post stenting outcomes in patients who were treated with the Wingspan stent on-label in the WEAVE trial. This includes both the assessment of any stroke, hemorrhage, or death, as well as assessment of delayed imaging results to determine the re-stenosis rate of the stents in these patients.

NCT ID: NCT04221763 Completed - Heart Failure Clinical Trials

Mechanisms and Innovations in Cardiac Resynchronisation Therapy

MIC
Start date: October 15, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effectiveness of multiple modalities of cardiac resynchronisation therapy using high precision acute electrical and haemodynamic measurements.These modalities include biventricular pacing and conduction system pacing utilising His bundle and left bundle pacing. Conduction system pacing is a more physiological form of pacing. The study hypothesises that this will produce more effective cardiac resynchronisation.

NCT ID: NCT04221191 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP

TEC-ADHERE
Start date: August 19, 2019
Phase:
Study type: Observational

The primary objective is to compare oral dimethyl fumarate (DMF) persistence at six months in relapsing-remitting multiple sclerosis (RR-MS) participants initiating DMF with and without OroSEP patient support program (PSP), respectively. The secondary objectives are: to compare oral DMF persistence at one month and three months in RR-MS participants initiating DMF with and without OroSEP PSP, respectively; To compare oral DMF adherence at six months in RR-MS participants initiating DMF with and without OroSEP PSP; To compare at three months and six months the reason of oral DMF discontinuation, in the two groups; To describe the percentage of participants with treatment-related adverse events globally and by class of adverse events, in the two groups of participants; To assess the evolution of participants' anxiety globally and to compare it at inclusion and at six months in participants with and without OroSEP PSP, respectively; To describe participants' satisfaction regarding oral DMF initiation and follow-up globally at six months and to compare it in patients with and without OroSEP PSP, respectively; For OroSEP PSP group: To assess participants' satisfaction regarding their participation in OroSEP PSP at six months; To assess neurologists' satisfaction regarding their participation in OroSEP PSP, after the last participant last visit of center.